Horizon Discovery Group plc Horizon Discovery hosts Capital Markets Day today (6154G)
March 05 2018 - 2:00AM
UK Regulatory
TIDMHZD
RNS Number : 6154G
Horizon Discovery Group plc
05 March 2018
Horizon Discovery Group plc
Horizon Discovery hosts Capital Markets Day today
Cambridge, UK, 5 March 2018: Horizon Discovery Group plc (LSE:
HZD) ("Horizon" or "the Group"), a global leader in gene editing
and gene modulation technologies, will today hold a Capital Markets
Day in London for institutional investors and analysts between
13:00 - 15:00 GMT / 08:00 - 10:00 EDT at Etc. Venues Fenchurch
Street, 43/44 Crutched Friars, London, EC3N 2HH. Registration for
those attending in person will begin at 12:30 to ensure a prompt
13:00 start. A light lunch will be provided. No new price sensitive
information will be disclosed.
The agenda for the session, commencing at 13:00 GMT / 08:00 EDT
today, will include:
-- Richard Vellacott, Interim Chief Executive Officer: Horizon Strategy and Vision
-- Richard Vellacott: FY17 Trading
-- Terry Pizzie, Head of Commercial: Commercial Delivery
-- Chris Lowe, Head of Research Operations: Delivery of our Research Operations
-- Kim Nichols, Head of Global Operations: Dharmacon Business and Integration
-- Jon Moore, Head of Translational R&D: Leveraged Research
-- Tom Henley, Head of Innovation: Driving our Core Innovation
-- Richard Vellacott: Summary and Q&A
The event will simultaneously be available via a live conference
call and webcast at
https://www.horizondiscovery.com/about-us/investor-relations. A
recording will be made available shortly after the event.
To dial in to the conference call, please follow these
numbers:
Dialling in from the UK: +44 (0)330 336 9411
Dialling in from the US: +1 929-477-0353
Confirmation code: 7131835
Please contact horizon@consilium-comms.com if you would like to
attend today's event and have not already registered.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Richard Vellacott, Interim Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUMUWUPRPPC
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024